SBIR/STTR Research Award

Open-top light-sheet microscopy for non-destructive 3D pathology of prostate biopsies

Award identifier c41d61e63ea0a35013e27db55d6df2e888a26373873176908364134a7279f7efAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$397,742

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ALPENGLOW BIOSCIENCES, INC.
Proposal award date
2020-09-05
Contract end date
2021-08-31
UEI
DVN2AF9A1YV3
Solicitation number
PAR18-303
Topic code
102

Research abstract

Abstract We are proposing a new approach for prostate cancer pathology using 3D open-top light-sheet (OTLS) microscopy and optical clearing. Approximately 20% of patients with an initial negative prostate biopsy procedure are found to have prostate cancer on a subsequent biopsy procedure. Previous studies have shown that examination of 100% of biopsy tissue improved prostate cancer detection rate, but these studies used labor-intensive manual sectioning techniques that are practical for a clinical laboratory. We hypothesize that imaging 100% of prostate biopsy tissue using OTLS microscopy, rather than 1-2% of the biopsy using current pathology technology, can detect occult carcinoma that would have otherwise been missed in a subset of patients. Furthermore, we intend to show that 3D OTLS can be seamlessly integrated into the current clinical laboratory workflow. The specific aims of this proposal are: 1) Validate that our OTLS methods do not interfere with the current pathology practice of formalin-fixed paraffin-embedded (FFPE) tissue sections, hematoxylin and eosin (Handamp;E) histology, and immunohistochemistry (IHC), and 2) To show that 3D pathology can detect occult cancer missed by traditional microscopy, we will compare diagnosis of “pseudo-Handamp;E” 3D OTLS images to traditional Handamp;E pathology. We will use archived FFPE biopsy blocks from patients with prostate cancer who had a negative initial biopsy result. Through the studies in this proposal, we will validate the non-interference of our innovative 3D OTLS methods with standard pathology practice, a necessary prerequisite for adoption within the pathology community and for regulatory considerations. We will also provide preliminary evidence to support the clinical value of 3D pathology. This project addresses the IMAT goal of developing substantially improved cancer detection and risk assessment technologies.The diagnosis of prostate cancer relies on centuries-old pathology technology, which has flaws that lead to undetected carcinoma in biopsy specimens. This project aims to develop innovative open-top light-sheet microscopy methods for prostate cancer pathology in two ways: 1) to demonstrate non-interference with the current standard of care methods, and 2) to provide preliminary evidence supporting the clinical value of the technology. The objectives of this proposal are consistent with the goals of the NCI IMAT SBIR program, which aims to support the early-stage development and validation of highly innovative technologies relevant to cancer diagnosis in the context of commercial use.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

5 SBIR/STTR records share this UEI (2020–2024). Reported award amounts total $3,363,736. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.